| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/15/1999 | EP0941243A1 Polypeptides comprising gax protein domains, involved in repressing transcription and/or interacting with other proteins, corresponding nucleic acids and their use |
| 09/15/1999 | EP0941227A1 Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents |
| 09/15/1999 | EP0941125A1 Methods for regulating angiogenesis |
| 09/15/1999 | EP0941122A2 Compositions and methods for polynucleotide delivery |
| 09/15/1999 | EP0941120A1 Branched peptide linkers |
| 09/15/1999 | EP0941089A2 Compositions and methods for treating or preventing inflammatory diseases |
| 09/15/1999 | EP0941084A1 Raf kinase inhibitors |
| 09/15/1999 | EP0941080A2 Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents |
| 09/15/1999 | EP0748383B1 Targeted cleavage of rna using ribonuclease p targeting and cleavage sequences |
| 09/15/1999 | EP0611304B1 Use of acetylated mannan (acemannan) for the regulation of blood cholesterol levels and for removing plaques in blood vessels |
| 09/15/1999 | CN1228783A Thrombin inhibitor |
| 09/15/1999 | CN1228779A Spirocyclic metalloprotease inhibitors |
| 09/15/1999 | CN1228777A Pyridyl alkene- and pyridyl alkine-acid amides as cytostatics and immunosuppressives |
| 09/15/1999 | CN1228775A Benzofurans and benzopyrans as chronobiological agents |
| 09/15/1999 | CN1228773A Heterocyclic metalloprotease inhibitors |
| 09/15/1999 | CN1228771A 1,3-diheterocyclic metalloprotease inhibitors |
| 09/15/1999 | CN1228707A Titanium slow-release composition |
| 09/15/1999 | CN1228704A Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazoles |
| 09/15/1999 | CN1228697A Method for in vivo reduction of iron levels and compositions useful therefor |
| 09/15/1999 | CN1228310A Xiaoaisan powder for curing cancer |
| 09/15/1999 | CN1045088C Purine and guanine compounds as inhibitors of PNP |
| 09/14/1999 | US5952504 Reacting a sulfonated, halogenated or phosphonated 1,7-naphthyridine compounds with an aromatic amine derivative; antiulcer agent |
| 09/14/1999 | US5952490 Oligonucleotides having a conserved G4 core sequence |
| 09/14/1999 | US5952483 Human IκB-β |
| 09/14/1999 | US5952481 DNA encoding ubiquitin conjugating enzymes |
| 09/14/1999 | US5952478 Nucleotides and analogs in which both the 3' oxy linkage and the 5' oxy linkage are replaced by carbon linkages; for antisense agents; viricides against influenza, herpes and human immune deficiency virus; anticarcinogenic agents |
| 09/14/1999 | US5952472 Anti-fibroblast growth factor-8 monoclonal antibody |
| 09/14/1999 | US5952382 Inhibiting the biological effects of an overregulation of retinoid acid receptors and/or of a hypervitaminosis a; treating skin disorder, eye vision defects, skin aging |
| 09/14/1999 | US5952381 Para-substituted phenylene derivatives |
| 09/14/1999 | US5952380 Method for treating diarrhea |
| 09/14/1999 | US5952366 Alkyl ether analogs of chlorins having an N-substituted imide ring |
| 09/14/1999 | US5952350 Naphthyl compounds and compositions, as estrogen receptor binding agents |
| 09/14/1999 | US5952342 1,6-naphthyridines effective in treating atherosclerosis, restenosis and psoriasis; anticarcinogenic and -proliferative agents; bactericides |
| 09/14/1999 | US5952333 Inhibitor of tyrosine kinase receptor for treating proliferative disease such as cancer |
| 09/14/1999 | US5952294 Peptidyl prodrugs and methods of making and using the same |
| 09/14/1999 | US5952232 Expandible microparticle intracellular delivery system |
| 09/14/1999 | US5952228 Isolated cytolytic T cells which are specific for complexes OF HLA- B35 molecules and the peptide PHE Pro Ser Asp Ser Trp Cys Tyr PHE, and uses thereof |
| 09/14/1999 | US5952221 A virion having a drug-sensitivity gene and a second gene capable of providing ancillary effects to solid tumor cells; gene therapy and antitumor agents |
| 09/14/1999 | US5952214 Human growth-related CDC10 homolog |
| 09/14/1999 | US5952199 A protein that contains an immunoglobulin-like domain; antiproliferative/antitumor agents, treatment of rheumatoid arthritis, psoriasis, diabeties, glaucoma, muscular disorders and immune rejection of eye transplants |
| 09/14/1999 | US5952181 Hybridizing polynucleotide sequence to complementary polynucleotide forming a complex, detecting complex formation; anticarcinogenic agent, treatment of psychological disorders, alzheimer's disease |
| 09/14/1999 | US5952175 DNA encoding a human progesterone receptor complex p23-like protein |
| 09/14/1999 | US5952002 Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or sequences of that virus coding therefor |
| 09/14/1999 | US5951985 Tumor associated epitope |
| 09/14/1999 | US5951979 Mutants (alanine replacing an aspartic acid) lack or have reduced catalytic activity but retain ability to bind substrate resulting in formation of observable and isolatable complex and less immunogenic effects |
| 09/14/1999 | US5951976 Vaccinating a mammal by administering a composition comprising an opsonin-enhanced cell comprising said selected antigen with the provision the opsonin does not bind to a receptor for a fragment of c33 |
| 09/14/1999 | US5951975 Immunization with a foreign artificial target antigen to promote a cytotoxic t-lymphocyte response; loading cultured tumor cells with antigen; deactivating the cells; immunizing with the cell to get a response to unmodified tumor |
| 09/14/1999 | US5951974 At least about 15%, preferably about 30%, of the interferon conjugates have a nonantigenic alkylpolyether attached to a preferential histidine residue; high activity; reacting an n-oxycarbonyloxyimide at acidic ph |
| 09/14/1999 | CA2012732C Production of modified pe40 |
| 09/10/1999 | WO1999045127A2 Enhanced prodrug activation |
| 09/10/1999 | WO1999045126A2 Enhanced prodrug activation |
| 09/10/1999 | WO1999045102A1 Method for activating natural killer (nk) cells |
| 09/10/1999 | WO1999045098A2 Delivery or proteins into eukaryotic cells with recombinant yersinia |
| 09/10/1999 | WO1999045031A2 Cd147 binding molecules as therapeutics |
| 09/10/1999 | WO1999045024A1 Cholenic acid amides and pharmaceutical compositions thereof |
| 09/10/1999 | WO1999045016A2 Novel prodrugs for phosphorus-containing compounds |
| 09/10/1999 | WO1999045015A1 5-imino-13-deoxy anthracycline derivatives, their uses, and processes for preparing them |
| 09/10/1999 | WO1999045009A1 Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors |
| 09/10/1999 | WO1999044998A1 Novel unsymmetrically substituted carboxylic acid derivatives, method for producing them, and their use as mixed eta/etb-receptor antagonists |
| 09/10/1999 | WO1999044994A1 Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists |
| 09/10/1999 | WO1999044989A1 Matrix metalloproteinase inhibitors |
| 09/10/1999 | WO1999044987A1 NON-PEPTIDE GnRH AGENTS |
| 09/10/1999 | WO1999044943A2 Vectors and viruses used in gene therapy |
| 09/10/1999 | WO1999044645A1 Compositions and methods of treating tumors |
| 09/10/1999 | WO1999044629A2 Utilization of cd137 in order to promote the proliferation of peripheral monocytes |
| 09/10/1999 | WO1999044628A1 Conjugates useful in the treatment of prostate cancer |
| 09/10/1999 | WO1999044600A1 Cancer management with tamoxifen and gammalinolenic acid |
| 09/10/1999 | WO1999044584A1 Emulsion preconcentrates containing cyclosporin or a macrolide |
| 09/10/1999 | WO1999033451A3 Mixture and pharmaceutical composition comprising z-4-hydroxytamoxifen and cyclodextrin |
| 09/10/1999 | WO1999032644A3 Prostate cancer gene |
| 09/10/1999 | WO1999032514A3 Sag: sensitive to apoptosis gene |
| 09/10/1999 | WO1999031262A3 Needle-free injection of formulated nucleic acid molecules |
| 09/10/1999 | WO1999027958A9 Hiv-1 tat, or derivatives thereof for prophylactic and therapeutic vaccination |
| 09/10/1999 | WO1999023078A3 Novel carboxylic acid derivatives which carry amide side chains, production of said carboxylic acid derivatives and their use as endothelin receptor antagonists |
| 09/10/1999 | WO1998053839A3 Anti-cancer products for treating cystic fibrosis |
| 09/10/1999 | CA2322856A1 Cancer management with tamoxifen and gammalinolenic acid |
| 09/10/1999 | CA2322749A1 Cd147 binding molecules as therapeutics |
| 09/10/1999 | CA2322712A1 Method for activating natural killer (nk) cells |
| 09/10/1999 | CA2322684A1 Utilization of cd137 in order to promote the proliferation of peripheral monocytes |
| 09/10/1999 | CA2322665A1 Delivery of proteins into eukaryotic cells with recombinant yersinia |
| 09/10/1999 | CA2322664A1 Enhanced prodrug activation |
| 09/10/1999 | CA2322592A1 Use of a peptide or antibody in the manufacture of a medicament for treating an erbb protein medicated tumor in combination with irradiation |
| 09/10/1999 | CA2322541A1 Novel unsymmetrically substituted carboxylic acid derivatives, method for producing them, and their use as mixed eta/etb-receptor antagonists |
| 09/10/1999 | CA2322444A1 Non-peptide gnrh agents |
| 09/10/1999 | CA2322207A1 Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists |
| 09/10/1999 | CA2321171A1 Conjugates useful in the treatment of prostate cancer |
| 09/10/1999 | CA2317502A1 Matrix metalloproteinase inhibitors |
| 09/10/1999 | CA2249661A1 Novel compounds |
| 09/09/1999 | DE19809144A1 Neue unsymmetrisch substituierte Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶LAMBDA¶/ET¶B¶-Rezeptorantagonisten New asymmetrically substituted carboxylic acid derivatives, their preparation and use as a mixed ET¶LAMBDA¶ / ET¶B¶ receptor antagonists |
| 09/09/1999 | DE19808889A1 Vektoren und Viren zur Gentherapie Vectors and viruses for gene therapy |
| 09/08/1999 | EP0940468A1 Humanized antibody variable domain |
| 09/08/1999 | EP0939824A1 Reagents and methods useful for detecting diseases of the breast |
| 09/08/1999 | EP0939821A2 G-beta-gamma regulated phosphatidylinositol-3' kinase |
| 09/08/1999 | EP0939820A1 Nucleic acid sequences that encode a cell growth regulatory protein and uses thereof |
| 09/08/1999 | EP0939819A1 Mini-e1a genes and gene products |
| 09/08/1999 | EP0939817A2 High-affinity interleukin-4 muteins |
| 09/08/1999 | EP0939815A1 IDENTIFICATION OF Bap-1, A PROTEIN THAT BINDS TO INTEGRIN AND IS INVOLVED IN INTEGRIN-MEDIATED SIGNAL TRANSDUCTION |
| 09/08/1999 | EP0939809A2 Tie-2 receptor ligands (tie ligand-3; tie ligand-4) and their uses |
| 09/08/1999 | EP0939807A2 Secreted proteins and polynucleotides encoding them |
| 09/08/1999 | EP0939806A1 Fanconi gene 1 |